ProfoundBio
ProfoundBio is a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer patients. Their pipeline includes several ADC drug candidates targeting solid tumors and hematological malignancies, focusing on innovative approaches for improved clinical outcomes. Key programs are currently in Phase 1 and 2 clinical trials.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $112M
Date: 13-Feb-2024
Investors: Ally Bridge Group, Nextech Invest, T. Rowe Price Associates, Inc., Janus Henderson Investors, RA Capital Management, OrbiMed, Surveyor Capital, Medicxi, Logos Capital, Octagon Capital, Piper Heartland Healthcare Capital, LifeSci Venture Partners, Lilly Asia Ventures (LAV), LYFE Capital
Markets: Biotechnology, Oncology, Antibody-drug conjugates (ADCs), Therapeutics
HQ: Seattle, Washington, United States
Founded: 2018
Website: https://www.profoundbio.com
LinkedIn: https://www.linkedin.com/company/profoundbio/
Crunchbase: https://www.crunchbase.com/organization/profoundbio
Leave a Comment
Comments
No comments yet.